An interventional study of Educational videos and Standard of Care in Sarcoma, sponsored by Mount Sinai Hospital, Canada. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Mount Sinai Hospital, Canada · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 145 studies in Sarcoma with a site in Canada — 21 open to participants now, 40 under way, 2 of them phase 3. Sarcoma · Canada.
Among the 145 studies in Sarcoma with a site in Canada, this one is the 53rd largest by planned enrollment of the 125 interventional ones that give a count, is one of 9 that started in 2025, is one of 13 with no phase, reaches primary completion later than 23 of the 39 other live ones, and was the 135th registered.
1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.
Browse Sarcoma studies →21 of the 145 studies in Sarcoma with a site in Canada are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Canada, United States, France and 3 more countries
Novartis Pharmaceuticals · Sites in Canada, United States, Denmark and 4 more countries
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
University of Calgary · Sites in Canada, United States
Ages 18+
Bayer · Sites in Canada, United States, Australia and 8 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
145 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 41 · Phase 2 75 · Phase 3 23
First in 1988; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 41 across 1,255 interventional studies indexed under Sarcoma.
Median enrollment 71 across the 125 interventional studies, 254 across the 8 observational. Of the 98 that completed or were terminated, 39 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 145 have an industry lead sponsor. The 10 most frequent:
Mount Sinai Hospital, Canada is the lead sponsor of 158 studies on the registry; 32 are open to participants now.
Mount Sinai Hospital, Canada has 3 studies filed under Sarcoma — fewer than ten, so there is no comparison to draw.
12 of the studies in Sarcoma with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03054792The Hospital for Sick ChildrenMolecular-Functional Imaging of Hypoxia in Childhood Sarcomas | 2026-12 |
| NCT03818412University Health Network, TorontoCirculating Tumor DNA in Soft Tissue Sarcoma | 2026-12-17 |
| NCT02923778National Cancer Institute (NCI)Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery | 2026-12-29 |
| NCT04901702St. Jude Children's Research HospitalStudy of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | 2026-12-31 |
| NCT07104682University of CalgaryA Study to Determine the Safety and Effectiveness of the Investigational Cellular Therapy GCAR1 in a Patient With Alveolar Soft Part Sarcoma | 2027-01-19 |
Add all 12 to your calendar (.ics) → With an account.
Among the 145 studies in Sarcoma with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate how sarcoma-specific educational videos improve patients' knowledge of their disease and treatment options before their first clinic appointment.
Participants will watch four educational videos before their first appointment with a medical oncologist. Participants will be asked to complete surveys to assess their understanding of sarcoma and its treatment options before and after their first medical oncology clinic appointment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Educational videos
Other: Standard of Care
Participants will be provided with four educational videos in clinic prior to their initial medical oncology consult.
Participants in the control arm will be provided with the educational videos after their consult with the medical oncologist.
Assess differences in patients' and caregivers' knowledge and perceptions of sarcoma and its treatment before and after educational intervention
Evaluate the changes in global responses between baseline surveys and post educational intervention surveys.
Time frame: up to 2 weeks (date when given appointment and date of first appointment)
Assess understandability and actionability of sarcoma educational videos.
The Patient Education Materials Assessment Tool (PEMAT) for Audiovisual Materials will be used to assess the video's understandability and actionability. The higher the score (\>80%), the more understandable or actionable the material.
Time frame: up to 2 weeks (date when given appointment and date of first appointment)
Assess understandability and actionability of sarcoma educational videos.
The Suitability Assessment of Materials (SAM) will be used for evaluation of health-related information for adults to objectively assess the suitability of these educational materials for sarcoma patients.
Time frame: up to 2 weeks (date when given appointment and date of first appointment)
Assess patient's and caregivers' satisfaction with the educational videos
Based on responses from a post-educational intervention survey. The scores will be measured using a Likert Scale (1-5), with higher scores indicating greater satisfaction.
Time frame: up to 2 weeks (date when given appointment and date of first appointment)
Plan to share: Yes — Only IPD used in the results publication will be shared.
Started May 2025 (actual). Primary completion is estimated for Dec 2027, 31 months after the start.
Of 145 non-industry interventional studies with no phase under Sarcoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 120. This study's planned 31 months is below that.
Counting every sponsor, half of 148 studies reached it within 59 months; a quarter within 34 and three quarters within 120.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Apr 2026 → Dec 2027 and completion Apr 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mount Sinai Hospital, Canada →